| Ytd | -78.15% | |
| 1y | -97.29% |
| Open | 1.46 | Prev Close | 1.47 | Low | 1.43 | High | 1.53 | Mkt Cap | 135.65K |
| Vol | 18.04K | Avg Vol | 65.73K | EPS | -52.02 | P/E | -0.03 | Forward P/E | -0.29 |
| Beta | -1.21 | Short Ratio | 0.10 | Inst. Own | 4.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.98 | 200-d Avg | 15.46 | 1yr Est | 11.50 |
GRI News
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market ses
Designation highlights significant regulatory milestone and provides a potential pathway to seven ye
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the pr
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consens
Issued claims further strengthen global intellectual property portfolio supporting immune cell modul
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the pr
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company ad
Met its primary endpoint, demonstrating favorable safety and tolerabilityMet multiple secondary endp
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company ad
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibros
GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company adv
GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lun
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treat
GRI Bio, Inc. (the "Company") has received topline data from the Phase 2a GRI-0621-IPF-02 cl
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the pr